Teva Obtains Approval For ProAir Digihaler In The US

Receiving FDA approval for its ProAir Digihaler (albuterol sulfate) inhalation powder is a “significant milestone” for Teva, as the firm reveals plans to make the device available in limited geographies in 2019, with a nationwide US launch set for 2020.

Milestone
Teva hits milestone with ProAir Digihaler approval in US • Source: Shutterstock

Teva has received US Food and Drug Administration (FDA) approval for its ProAir Digihaler (albuterol sulfate) 117μg inhalation powder device, “the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler-use information to people with asthma and chronic obstructive pulmonary disease (COPD)”.

The prescription medicine is used to treat or prevent bronchospasm in patients with reversible obstructive airway disease and to prevent...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin